23
Aug
Aug
A plain-language comparison of BPC-157 and GHK-Cu: structure, size, the pathways each is studied through, the research areas each belongs to, and what neither has been tested for in people.
23
Aug
Aug
What the published record actually reports about BPC-157 safety: no Phase II or III human efficacy trial, small pilot infusion references, and open questions.
Regulatory & Legal, Research Education
Is BPC-157 FDA Approved? Regulatory Status Explained | Artemis Labs
23
Aug
Aug
BPC-157 is not an FDA-approved drug. What that means, the 2023-2026 compounding timeline, and how “approved,” “scheduled,” and “compounding list” differ.
Regulatory & Legal, Research Education
Are There Human Trials of BPC-157? The Honest Answer | Artemis Labs
23
Aug
Aug
A plain answer to a question most sellers avoid: no Phase II or III human trial of BPC-157 has ever been published. Here is what the human record actually holds.
23
Aug
Aug
How standalone BPC-157 differs from the pre-mixed blends that contain it, what is in each vial, and why combining peptides is a research idea, not a proven bigger effect.
Pillar guide to recovery research peptides — BPC-157, TB-500, KPV, GHK-Cu — covering the three-phase repair cascade and 2024–2026 stack research.
What published research actually says about BPC-157 and TB-500 — sequences, study models, human-evidence gaps, and why no combination study exists.
Deep dive on GLP-1 receptor agonism — binding affinities, signaling cascades, GIP/GLP-1 dual agonism, and triple-agonist research from 2024–2026 literature.
SLU-PP-332 ERRα agonist deep dive — mechanism, the 2023 Saint Louis University publication, exercise-mimetic transcriptional signature, and 2024-2026 follow-up research.
Pillar guide to longevity research peptides — MOTS-C, SS-31 (elamipretide), SLU-PP-332, GHK-Cu, 5-Amino-1MQ — mechanisms, 2024–2026 data, and comparative pharmacology.